FosB protein in laryngeal cancer and prognosis
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This study looks at a protein called FosB in laryngeal cancer tissue to see if it relates to patient outcomes. It may help doctors understand how the cancer behaves and predict prognosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of laryngeal squamous cell carcinoma (a type of throat cancer).
- The cancer should be a primary tumor and not have spread to other parts of your body (no distant metastasis).
- You should be planning to start standard treatment (like surgery) for the first time, not have received treatment elsewhere.
- Your complete medical records must be available, and you need to agree to follow-up after treatment.
- You must not have a history of other serious or life-threatening diseases, such as another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria and other microbes in lung cancer tissue to understand how they might affect the disease. It may help find new ways to treat or manage non-small cell lung cancer.
This study looks at the outlook for people with liver cancer who have not yet started any cancer treatment. It aims to learn more about how the disease progresses over time.
This study looks at how a protein called FGF19 relates to the outlook (prognosis) of liver cancer. It may help doctors better understand the disease.
This study looks at “biomarkers” (measurable signals in samples) taken during bronchoscopy or related procedures in people with severe airway pre-cancer or certain lung/throat cancers, and in healthy volunteers. The goal is to better understand what these biomarkers mean and how they might help with diagnosis, staging, or monitoring.
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
Hear when a new Laryngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.